Dr. David Berz
Claim this profileValkyrie Clinical Trials
Studies Non-Small Cell Lung Cancer
Studies Tumors
18 reported clinical trials
32 drugs studied
Area of expertise
1Non-Small Cell Lung Cancer
Stage III
Stage IV
PD-L1 positive
2Tumors
Stage IV
KRAS positive
Stage III
Affiliated Hospitals
Clinical Trials David Berz is currently running
BDTX-1535 + Temozolomide
for Glioblastoma and Lung Cancer
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of BDTX-1535. The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma multiforme (GBM) expressing EGFR alterations (Phase 1 only). All patients will self administer BDTX-1535 monotherapy by mouth in 21-day cycles. Phase 1 enrollment is now complete. Phase 2 is currently enrolling.
Recruiting1 award Phase 1 & 214 criteria
Zotatifin
for Solid Tumors
This trial is testing a new drug called Zotatifin for patients with advanced cancers that haven't improved with standard treatments. The drug works by stopping cancer cells from making essential proteins, which may slow or stop the cancer.
Recruiting3 awards Phase 1 & 221 criteria
More about David Berz
Clinical Trial Related2 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments David Berz has experience with
- Pembrolizumab
- Trilaciclib
- Docetaxel
- H002
- BMS-986466
- Adagrasib
Breakdown of trials David Berz has run
Non-Small Cell Lung Cancer
Tumors
Cancer
Solid Tumors
Lung Cancer
- BDTX-1535 + Temozolomide for Glioblastoma and Lung Cancer
- Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)
- Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David Berz specialize in?
David Berz focuses on Non-Small Cell Lung Cancer and Tumors. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage III patients, or patients who are Stage IV.
Is David Berz currently recruiting for clinical trials?
Yes, David Berz is currently recruiting for 9 clinical trials in Los Angeles California. If you're interested in participating, you should apply.
Are there any treatments that David Berz has studied deeply?
Yes, David Berz has studied treatments such as Pembrolizumab, Trilaciclib, Docetaxel.
What is the best way to schedule an appointment with David Berz?
Apply for one of the trials that David Berz is conducting.
What is the office address of David Berz?
The office of David Berz is located at: Valkyrie Clinical Trials, Los Angeles, California 90067 United States. This is the address for their practice at the Valkyrie Clinical Trials.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.